Drug Trial Radar · NCT06647550
To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
Last checked: Nov 19, 2026Latest source record: Dec 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Dec 12, 2024
Primary completion
Mar 31, 2025
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Hyundai PharmIndustry
- Sponsor type
- Industry
- First posted
- Oct 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
Conditions
- Type 2 Diabetes Mellitus (T2DM)
Interventions
HD-6277 100mgDrug
PO, QD
HD-6277 50mgDrug
PO, QD
HD-6277 25mgDrug
PO, QD
PlaceboDrug
PO, QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- change in HbA1c at weeks 12 from baselineTime frame: at weeks 12 from baseline
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Korea University Anam Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.